Clinical Trials
4 trialsNCT03302728 2022-05-19
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT01196208 2020-09-21
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Seagen Inc.
No longer available
NCT00051597 2011-10-12
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Seagen Inc.
Phase 1/2 Completed